2021
Polyclonality Strongly Correlates with Biological Outcomes and Is Significantly Increased Following Improvements to the Phase 1/2 HGB-206 Protocol and Manufacturing of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy (GT)
Tisdale J, Thompson A, Mapara M, Kwiatkowski J, Krishnamurti L, Aygun B, Kasow K, Rifkin-Zenenberg S, Schmidt M, Pierciey F, Whitney D, Rogers C, Nnamani M, Foos M, Miller A, Zhang X, Lynch J, Walters M, Kanter J, Bonner M. Polyclonality Strongly Correlates with Biological Outcomes and Is Significantly Increased Following Improvements to the Phase 1/2 HGB-206 Protocol and Manufacturing of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy (GT). Blood 2021, 138: 561. DOI: 10.1182/blood-2021-147760.Peer-Reviewed Original ResearchAcute myeloid leukemiaVaso-occlusive eventsCurrent equity holderSevere vaso-occlusive eventsGroup AGroup CMonth 6Clinical outcomesBluebird BioClinical benefitBusulfan conditioningCell doseRisk of AMLAutologous stem cell transplantTricuspid regurgitant jet velocityAdvisory CommitteeDriver mutationsLentiviral vectorsAML driver mutationsOpioid withdrawal syndromeSerious adverse eventsRegurgitant jet velocityFavorable clinical outcomeConsultancy feesStem cell transplant
2019
Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study
Krishnamurti L, Neuberg D, Sullivan K, Kamani N, Abraham A, Campigotto F, Zhang W, Dahdoul T, De Castro L, Parikh S, Bakshi N, Haight A, Hassell K, Loving R, Rosenthal J, Smith S, Smith W, Spearman M, Stevenson K, Wu C, Wiedl C, Waller E, Walters M. Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. American Journal Of Hematology 2019, 94: 446-454. PMID: 30637784, PMCID: PMC6542639, DOI: 10.1002/ajh.25401.Peer-Reviewed Original ResearchConceptsSevere sickle cell diseaseBone marrow transplantationEvent-free survivalSickle cell diseaseMarrow transplantationCell diseaseElevated tricuspid regurgitant jet velocityRegular red blood cell transfusionsSevere SCDDonor bone marrow transplantationOne-year overall survivalSecond bone marrow transplantationTricuspid regurgitant jet velocityRed blood cell transfusionProspective multicenter pilot studyDeveloped chronic GVHDHost disease (GVHD) prophylaxisStable donor chimerismAcute chest syndromeSecondary graft failureBlood cell transfusionHealth-related qualityPhysical function domainProspective clinical trialsRegurgitant jet velocity
2012
Risk Factors for Death in 632 Patients with Sickle Cell Anemia in the United States and United Kingdom
Gladwin M, Barst R, Gibbs J, Hildesheim M, Sachdev V, Nouraie M, Hassell K, Little J, Schraufnagel D, Krishnamurti L, Novelli E, Girgis R, Zhang Y, Morris C, Rosenzweig E, Badesch D, Lanzkron S, Castro O, Taylor J, Goldsmith J, Gordeuk V, Kato G, Machado R. Risk Factors for Death in 632 Patients with Sickle Cell Anemia in the United States and United Kingdom. Blood 2012, 120: 3240. DOI: 10.1182/blood.v120.21.3240.3240.Peer-Reviewed Original ResearchTricuspid regurgitant jet velocityHigher tricuspid regurgitant jet velocityProportional hazards regression analysisHigher NT-proBNPUnadjusted hazard ratioNT-proBNPHazards regression analysisSickle cell diseasePulmonary hypertensionRisk factorsGlaxo Smith KlineAspartate aminotransferaseHazard ratioCell diseaseCox proportional hazards regression analysisMean pulmonary artery pressureSix-minute walk distanceSickle cell disease patientsPopulation screening studiesPulmonary artery pressureRight heart catheterizationRegurgitant jet velocityRisk of deathDoppler echocardiographic measurementsScreening study
2010
Predictors of Six-Minute Walk Distance In Adults with Sickle Cell Anemia In the Walk-PHaSST Study
Barst R, Kato G, Sachdev V, Nouraie M, Machado R, Hassell K, Gibbs S, Little J, Schraufnagel D, Krishnamurti L, Girgis R, Morris C, Badesch D, Lanzkron S, Castro O, Rosenzweig E, Goldsmith J, Gladwin M, Gordeuk V. Predictors of Six-Minute Walk Distance In Adults with Sickle Cell Anemia In the Walk-PHaSST Study. Blood 2010, 116: 947. DOI: 10.1182/blood.v116.21.947.947.Peer-Reviewed Original ResearchHigher tricuspid regurgitation velocityTricuspid regurgitation velocitySickle cell diseaseSickle cell anemiaRight ventricular systolic pressureVentricular filling pressureVentricular systolic pressureCell anemiaCell diseaseEa ratioExercise capacitySystolic pressureFilling pressureFunctional capacityHemolytic componentElevated tricuspid regurgitant jet velocityTricuspid regurgitant jet velocitySix-minute walk distanceSix-minute walk testSickle cell disease patientsDecreased exercise capacityHemoglobin oxygen desaturationBaseline clinical characteristicsImpaired exercise capacitySickle cell anemia patients
2006
Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease
Ambrusko S, Gunawardena S, Sakara A, Windsor B, Lanford L, Michelson P, Krishnamurti L. Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease. Pediatric Blood & Cancer 2006, 47: 907-913. PMID: 16496290, DOI: 10.1002/pbc.20791.Peer-Reviewed Original ResearchConceptsElevated tricuspid regurgitant velocityTricuspid regurgitant velocitySickle cell diseaseAcute chest syndromePulmonary hypertensionCerebrovascular diseaseVasoocclusive crisisSCD patientsReticulocyte countCell diseaseType of SCDTricuspid regurgitant jet velocityLife-threatening complicationsObstructive sleep apneaPediatric SCD patientsRegurgitant jet velocityElevated reticulocyte countSignificant differencesNumber of echocardiogramsChest syndromeEchocardiographic evidenceOutpatient echocardiogramMean hemoglobinClinical characteristicsHydroxyurea therapy
2005
Pulmonary Hypertension in Children with Sickle Cell Disease: Clinical Characteristics and Co-Morbidities.
Ambrusko S, Gunawardena S, Sakara A, Windsor B, Lanford L, Michelson P, Krishnamurti L. Pulmonary Hypertension in Children with Sickle Cell Disease: Clinical Characteristics and Co-Morbidities. Blood 2005, 106: 3791. DOI: 10.1182/blood.v106.11.3791.3791.Peer-Reviewed Original ResearchSickle cell diseasePulmonary hypertensionCell diseaseSilent strokeHepatitis CClinical characteristicsAplastic crisisCerebrovascular diseaseTransfusion therapyNocturnal enuresisTR jetTricuspid regurgitant jet velocityChronic transfusion programMoya-Moya syndromeTR jet velocityAcute chest syndromeElevated total bilirubinRestrictive lung diseaseMajority of patientsObstructive sleep apneaRegurgitant jet velocityCell-directed therapiesMiddle cerebral arteryRetrospective case reviewSickle cell patients